Profile Response Detail

Molecular Profile Unknown unknown
Therapy AMG820
Indication/Tumor Type Advanced Solid Tumor
Response Type no benefit
Create By cstatz
Update By cstatz

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor no benefit AMG820 Phase I Actionable In a Phase I trial, AMG 820 treatment was well-tolerated and resulted in safety, however, demonstrated limited antitumor activity in patients with advanced solid tumors, and thus, AMG 820 therapy combined with an immunotherapy was suggested based on clinical and preclinical evidence (PMID: 28655795). 28655795
PubMed Id Reference Title Details
(28655795) First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Full reference...